Likuiditas cepet daxor.com (DXR)

Daxor Corporation (DXR) creates benchmark blood volume monitoring systems targeting intensivists and cardiac surgeons within the critical care segment. Management aims to integrate these high-precision methods into general treatment protocols through physician training. This price chart, where the indicator equals 236.83, complements data on the stable cash flow the company generates through the leasing and sale of its unique diagnostic complexes.

The quick ratio assesses a company's ability to instantaneously settle short-term liabilities by excluding illiquid inventories and relying solely on cash and accounts receivable. An analysis of the ratio of cash and receivables to short-term debt confirms the financial stability of Daxor Corporation (DXR), whose patents and monopoly status in US clinics ensure a steady capital inflow even under rigorous FDA audits.